摘要
目的探讨重组人干扰素α1b、更昔洛韦联用对传染性单核细胞增多症(IM)患儿微炎症状态及免疫功能的影响。方法选取2019年4月至2021年2月辽宁省妇幼保健院收治的108例IM患儿作为研究对象,按随机数字表法分为对照组与观察组,各54例。对照组给予更昔洛韦治疗,观察组接受重组人干扰素α1b、更昔洛韦联用治疗,比较两组的治疗效果。结果观察组治疗有效率为96.30%,较对照组83.33%高(P<0.05);治疗后观察组白细胞介素-18(IL-18)、白细胞计数(WBC)、肿瘤坏死因子-α(TNF-α)较对照组低(P<0.05);治疗后观察组CD4^(+)较对照组高,CD3^(+)、CD8+较对照组低,差异有统计学意义(P<0.05);观察组并发症发生率较对照组低(P<0.05)。结论重组人干扰素α1b、更昔洛韦联用于治疗IM效果满意,可有效改善患儿机体微炎症状态,提高免疫功能,同时还能降低并发症发生率。
Objective To investigate the effect of ganciclovir combined with ganciclovir on microinflammatory state and immune function in children with infectious mononucleosis. Methods A total of 108 children with infectious mononucleosis admitted to Maternal and Child Health Hospital of Liaoning Province from April 2019 to February 2021 were randomly selected as the research objects and were divided into a control group and an observation group by random number table method. A total of 54 cases in the control group were given ganciclovir, while the observation group were given recombinant human interferon α-1 b,ganciclovir combined treatment, compared 2 groups of micro inflammatory state and immune function changes after treatment.Results the total effective rate of the observation group was 96.30%, which was higher than 83.33% of the control group(P<0.05);after treatment, the levels of IL-18, WBC and TNF in the observation group were significantly lower than those in the control group(P<0.05);after treatment, the CD4^(+) index of the observation group was higher than that of the control group, and the CD3^(+)and CD8+ index levels of the observation group were lower than those of the control group(P<0.05);after treatment, the incidence of respiratory tract infection, pneumonia, lymphadenopathy, and obstructive anemia in the 2 groups was lower than that in the control group(P < 0.05). Conclusion recombinant human interferon α-1 b, ganciclovir in the treatment of infectious mononucleosis effect is satisfactory, can effectively improve the body micro inflammatory state, improve immune function, but also reduce the incidence of complications, worthy of promotion.
作者
王莹
谭春迎
赵静
WANG Ying;TAN Chun-Ying;ZHAO Jing(Department of Pediatrics,Maternal and Child Health Hospital of Liaoning Province,Shenyang 110000,China)
出处
《中国药物经济学》
2022年第2期110-113,共4页
China Journal of Pharmaceutical Economics
